Search Results - "Calcagno, F."

Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study by Barthélémy, P., Albigès, L., Escudier, B., Narciso, B., Bigot, P., Chehimi, M., Emambux, S., Calcagno, F., Mouillet, G., Eymard, J.-C., Schlürmann, F., Bailly, S., Garbay, D., Berdah, J.-F., Palmaro, M.B., Goupil, M.G., Spaeth, D., Néré, S., Quentric, C., Vano, Y.-A., Thiery-Vuillemin, A.

“…Nivolumab is the first immune checkpoint inhibitor approved in Europe for the treatment of advanced renal cell carcinoma (aRCC) in patients resistant to prior…”
Get full text

3432 Metronomic cyclophosphamide (MC) treatment for heavily pre-treated metastatic Soft Tissue Sarcoma (mSTS) by Simon, P, Calcagno, F, Klajer, E, Meynard, G, Delroeux, D, Aubry, S, Pauchot, J, Valmary-Degano, S, Nerich, V, Kalbacher, E, Isambert, N, Chaigneau, L

Get full text

2345 Neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (dcf) compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma by Kim, S, Paget-Bailly, S, Fiteni, F, Messager, M, Nguyen, T, Mathieu, P, Lamfichekh, N, Fein, F, Fratte, S, Cleau, D, Calcagno, F, Lakkis, Z, Jary, M, Sakek, N, Jacquin, M, Foubert, A, Bonnetain, F, Mariette, C, Borg, C

Get full text

674P WITNESS: Real-world outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with nivolumab in France and subgroup analysis of patients receiving concomitant medications at baseline by Thiery-Vuillemin, A., Albiges, L., Escudier, B., Narciso, B., Bigot, P., Eymard, J-C., Calcagno, F., Schlürmann, F., Chehimi, M., Barthomeuf, J., Quentric, C., Vano, Y., Barthelemy, P.

Get full text

Congrès Targeted Anticancer Therapies — TAT 2014 by Bellesoeur, A., Brunot, A., Calcagno, F., Grellety, T., Loirat, D., Tabouret, E., Tlemsani, C., Sajous, C., Vicier, C., Rousseau, B., Soria, J. -C.

“…Résumé Les actualités majeures des thérapies ciblées antitumorales se sont discutées lors de la dernière édition du congrès TAT (Targeted Anticancer Therapies)…”
Get full text

509TiP REPROGRAM-01, a phase II study of regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer by Klajer, E., Jary, M., Borg, C., Kim, S., Vernerey, D., Henriques, J., N'Guyen, T., Nasri, M., Almotlak, H., Babre, J., Meurisse, A., Fratte, S., Fein, F., Calcagno, F., Chanut, L., Spehner, L., Rebucci-Peixoto, M., Vienot, A.

Get full text

1629P Increased incidence of thymic epithelial tumors during COVID-19 pandemic: A retrospective analysis from the French RYTHMIC network by Benitez, J.C., Florez-Arango, J., Boucher, M-E., Dansin, E., Kerjouan, M., Bigay-Game, L., Pichon, E., Thillays, F., Falcoz, P-E., Lyubimova, S., Oulkhouir, Y., Calcagno, F., Thiberville, L., Clément-Duchêne, C., Westeel, V., Thomas, P.A., Maury, J-M., Molina, T., Girard, N., Besse, B.

Get full text

991TiP - PULSE: A single arm trial assessing the activity and safety of avelumab immunotherapy maintenance among patients with locally advanced or metastatic squamous cell penile carcinoma (mSCPC) by Gassian, N., Mouillet, G., Vernerey, D., Manseur, O., Frontczak, A., Meurisse, A., Berthod, D., Robert, E., Calcagno, F., Thiery-Vuillemin, A.

“…mSCPC is an orphan disease with a poor prognosis. First line systemic treatment relies on platinum-based polychemotherapies (PBPC). These combinations remain…”
Get full text

991TiPPULSE: A single arm trial assessing the activity and safety of avelumab immunotherapy maintenance among patients with locally advanced or metastatic squamous cell penile carcinoma (mSCPC) by Gassian, N, Mouillet, G, Vernerey, D, Manseur, O, Frontczak, A, Meurisse, A, Berthod, D, Robert, E, Calcagno, F, Thiery-Vuillemin, A

“…Abstract Background mSCPC is an orphan disease with a poor prognosis. First line systemic treatment relies on platinum-based polychemotherapies (PBPC). These…”
Get full text

PULSE: A single arm trial assessing the activity and safety of avelumab immunotherapy maintenance among patients with locally advanced or metastatic squamous cell penile carcinoma (mSCPC) by Gassian, N., Mouillet, G., Vernerey, D., Manseur, O., Frontczak, A., Meurisse, A., Berthod, D., Robert, E., Calcagno, F., Thiery-Vuillemin, A.

Get full text

1878P Health-related quality of life (HRQoL) assessment for patients with advanced renal cell carcinoma (aRCC) treated with a tyrosine kinase inhibitor (TKI) using electronic patient reported outcomes in daily clinical practice: QUANARIE trial by Mouillet, G., Falcoz, A., Barthélémy, P., Geoffrois, L., Ladoire, S., Eymard, J-C., Plaza, J., Viel, E., Maurina, T., Calcagno, F., Stein, U., Fritzsch, J., Djoumakh, O., Paget-Bailly, S., Thiery-Vuillemin, A.

Get full text

1742TiP RADIORYTHMIC: Phase III, opened, randomized study of post-operative radiotherapy (PORT) versus surveillance in stage IIb/III of Masaoka Koga thymoma after complete surgical resection by Basse, C., Botticella, A., Molina, T., Falcoz, P-E., Oulkhouir, Y., Kerjouan, M., Pichon, E., Calcagno, F., Thiberville, L., Quantin, X., Clément-Duchêne, C., Khalifa, J., Mazieres, J., Le Tinier, F., Dansin, E., Thillays, F., Besse, B., Thomas, P-A., Le Pechoux, C., Girard, N.

Get full text

53P Studying autoimmune diseases with thymic epithelial tumors (TET): Real-world insight from RYTHMIC by Benitez, J.C., Boucher, M-E., Dansin, E., Kerjouan, M., Bigay-Game, I., Pichon, E., Thillays, F., Falcoz, P.E., Lyubimova, S., Oulkhouir, Y., Calcagno, F., Thiberville, L., Clément-Duchêne, C., Morin, F., Missy, P., Thomas, P., Maury, J., Molina, T., Girard, N., Besse, B.

Get full text

1899P Autoimmune diseases in centrally reviewed thymic epithelial tumours (TET) by Montanez, J.C. Benitez, Boucher, M-É., Dansin, E., Kerjouan, M., Mazieres, J., Pichon, E., Thillays, F., Falcoz, P.E., Roch, B., Oulkhouir, Y., Calcagno, F., Thiberville, L., Clément-Duchêne, C., Morin, F., Missy, P., Thomas, P.A., Maury, J.-M., Molina, T., Girard, N., Besse, B.

Get full text

P177 WITNESS : Real-world outcomes of nivolumab (NIVO) in patients (pts) with previously treated advanced renal cell carcinoma (aRCC) in France - final analysis and outcomes in elderly patients by Vano, Y.A., Barthelemy, P., Narciso, B., Bigot, P., Chehimi, M., Emambux, S., Calcagno, F., Mouillet, G., Schlürmann, F., Thiery-Vuillemin, A., Nere, S., Petit, G., Escudier, B., Albigès, L.

Get full text

Studying autoimmune diseases with thymic epithelial tumors (TET): Real-world insight from RYTHMIC by Benitez, Jc, Boucher, Me, Dansin, E, Kerjouan, M, Bigay-Game, I, Pichon, E, Thillays, F, Falcoz, Pierre-Emmanuel, Lyubimova, S, Oulkhouir, Y, Calcagno, F, Thiberville, L, Clement-Duchene, C, Morin, F, Missy, P, Thomas, P, Maury, J, Molina, T, Girard, N, Besse, B

Get full text

Autoimmune diseases in centrally reviewed thymic epithelial tumours (TET) by Benitez Montanez, Jc, Boucher, Me, Dansin, Eric, Kerjouan, M, Mazieres, J, Pichon, Eric, Thillays, François, Falcoz, Pierre-Emmanuel, Roch, B, Oulkhouir, Youssef, Calcagno, F, Thiberville, Luc, Clement-Duchene, C, Morin, F, Missy, P, Thomas, Pascal-Alexandre, Maury, Jean-Michel, Molina, T, Girard, Nicolas, Besse, Benjamin

“…BackgroundThere have been wide variations in the reported prevalence (up to 30%) of autoimmune disorders (AID) in TET patients (pts) in small single-center…”
Get full text

Updated data of epitopes-HPV02 trial and external validation of efficacy of DCF in prospective epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients by Kim, S., Meurisse, A., Stouvenot, M., Jary, M., Hon, T Nguyen Tan, Francois, E., Buecher, B., Andre, T., Samalin, E., Boulbair, F., De Bari, B., Almotlak, H., Klajer, E., Calcagno, F., Chatillon, E., Spehner, L., Jacquin, M., Vendrely, V., Vernerey, D., Borg, C.

Get full text

534P - Updated data of epitopes-HPV02 trial and external validation of efficacy of DCF in prospective epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients by Kim, S., Meurisse, A., Stouvenot, M., Jary, M., Hon, T Nguyen Tan, Francois, E., Buecher, B., Andre, T., Samalin, E., Boulbair, F., De Bari, B., Almotlak, H., Klajer, E., Calcagno, F., Chatillon, E., Spehner, L., Jacquin, M., Vendrely, V., Vernerey, D., Borg, C.

“…The addition of docetaxel to cisplatin and 5FU (DCF) has shown a promising efficacy in Epitopes-HPV01 study with 4 of first 8 consecutive patients presenting a…”
Get full text

534PUpdated data of epitopes-HPV02 trial and external validation of efficacy of DCF in prospective epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients by Kim, S, Meurisse, A, Stouvenot, M, Jary, M, Hon, T Nguyen Tan, Francois, E, Buecher, B, Andre, T, Samalin, E, Boulbair, F, Bari, B De, Almotlak, H, Klajer, E, Calcagno, F, Chatillon, E, Spehner, L, Jacquin, M, Vendrely, V, Vernerey, D, Borg, C

“…Abstract Background The addition of docetaxel to cisplatin and 5FU (DCF) has shown a promising efficacy in Epitopes-HPV01 study with 4 of first 8 consecutive…”
Get full text